These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3297425)

  • 1. Effects of sample preparation on cyclosporin G (NVA2-cyclosporin) concentration.
    Yatscoff RW; Jeffrey JR
    Clin Chem; 1987 Jul; 33(7):1257. PubMed ID: 3297425
    [No Abstract]   [Full Text] [Related]  

  • 2. High-performance liquid chromatographic analysis of cyclosporin G (Nva2-cyclosporine) in human blood.
    Annesley TM; Matz K; Leichtman AB
    Ther Drug Monit; 1992 Oct; 14(5):397-401. PubMed ID: 1448848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantification of cyclosporin G (NVa2 cyclosporin) by radioimmunoassay.
    Yatscoff RW; Jeffery JR
    Clin Chem; 1986 Apr; 32(4):700-1. PubMed ID: 3955826
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of cyclosporin G (Nva2-cyclosporin) concentrations measured in whole blood by monoclonal fluorescence polarization immunoassay, monoclonal radioimmunoassay, and HPLC.
    Annesley TM; Coombs RC; Orsulak PJ
    Clin Chem; 1993 Jun; 39(6):1050-3. PubMed ID: 8504536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (Nva2)-cyclosporine--less potent than cyclosporine A in rats with lung and heart transplants.
    Prop J; Hoyt EG; Jamieson SW
    Transplantation; 1987 Jul; 44(1):5-8. PubMed ID: 3111038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of metabolism in HepG2 cells upon treatment with cyclosporin A and Nva2-cyclosporin.
    Bäckman L; Appelkvist EL; Sundberg A; Teclebrhan H; Brunk U
    Exp Mol Pathol; 1991 Jun; 54(3):242-54. PubMed ID: 1647968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of cyclosporin G (NVa2 cyclosporin) in blood and plasma.
    Yatscoff RW; Honcharik N; Lukowski M; Thliveris J; Chackowsky P; Faraci C
    Clin Chem; 1993 Feb; 39(2):213-7. PubMed ID: 8432008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canine liver transplantation under Nva2-cyclosporine versus cyclosporine.
    Todo S; Porter KA; Kam I; Lynch S; Venkataramanan R; DeWolf A; Starzl TE
    Transplantation; 1986 Mar; 41(3):296-300. PubMed ID: 3513388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: II. Reduction of glomerulonephritis.
    Gunn HC; Ryffel B
    Clin Exp Immunol; 1986 May; 64(2):234-42. PubMed ID: 3742874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of cyclosporine A and Nva2-cyclosporine (cyclosporine G) in a rat renal allograft model.
    Grant D; Zhong R; Stiller C; Wallace C; Keown P; Duff J
    Transplantation; 1987 Jul; 44(1):9-12. PubMed ID: 3299927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of autoimmunity in (NZB X NZW)F1 mice with cyclosporin and (Nva2)-cyclosporin: I. Reduction of autoantibodies.
    Gunn HC
    Clin Exp Immunol; 1986 May; 64(2):225-33. PubMed ID: 3488856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The isolation, structural characterization, and immunosuppressive activity of cyclosporin G (NVa2-cyclosporine) metabolites.
    Copeland KR; Yatscoff RW
    Ther Drug Monit; 1991 Jul; 13(4):281-8. PubMed ID: 1780958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of hematocrit on cyclosporine (cyclosporin A) in whole blood and plasma of renal-transplant patients.
    Rosano TG
    Clin Chem; 1985 Mar; 31(3):410-2. PubMed ID: 3882273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotransformation of cyclosporin G in comparison to cyclosporine.
    Mangold JB; Schran HF; Yatscoff RW; Weitzel WF; Leichtman AB
    Transplant Proc; 1994 Oct; 26(5):3013-6. PubMed ID: 7940950
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of Nva2-cyclosporine on glomerular filtration rate and renal blood flow in the rat.
    Paller MS; Ferris TF
    Transplantation; 1987 Jun; 43(6):893-5. PubMed ID: 3590301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative pharmacokinetics of cyclosporine and NVa2-cyclosporine in dogs.
    Venkataramanan R; Todo S; Zaghloul I; Lynch S; Kam I; Ptachcinski RJ; Burckart GJ; Starzl TE
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1265-6. PubMed ID: 3274314
    [No Abstract]   [Full Text] [Related]  

  • 17. Cross-reactivities of cyclosporin G (NVa2 cyclosporin) and metabolites in cyclosporin A immunoassays.
    Yatscoff RW; Langman LJ; LeGatt DF
    Clin Chem; 1993 Jun; 39(6):1089-92. PubMed ID: 8504544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An assessment of Nva2-cyclosporine in primate cardiac transplantation.
    Ogunnaike HO; Starkey TD; Baldwin JC; Porter KA; Billingham ME; Jamieson SW
    Transplantation; 1987 Jan; 43(1):13-7. PubMed ID: 3541313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between cyclosporin and erythromycin in a kidney transplant patient.
    Kessler M; Louis J; Renoult E; Vigneron B; Netter P
    Eur J Clin Pharmacol; 1986; 30(5):633-4. PubMed ID: 3530783
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclosporin: measurement of fraction unbound in plasma.
    Legg B; Rowland M
    J Pharm Pharmacol; 1987 Aug; 39(8):599-603. PubMed ID: 2888849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.